Small Pharma team
Source: Small Pharma team
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • First Patient dosed in Small Pharma’s Phase I study exploring intramuscular administration of SPL026
  • The study will compare the profile of intramuscular versus intravenous SPL026 administration
  • This study seeks to identify a target dose of SPL026 administered via IM injection
  • The company’s current focus is exploring new therapeutic approaches for depression
  • Small Pharma (DMT) is up over 5.50 per cent, trading at C$0.10 at 2:31 pm EST

Small Pharma (DMT) announced that the first patient has been dosed in its Phase I study exploring intermuscular administration of SPL026.

Small Pharma’s lead candidate, SPL026, is a proprietary synthetic formulation of DMT. 

The goal of the study, being conducted in the United Kingdom, is to compare SPL026 delivered via IM versus IV administration in up to 14 healthy volunteers.

Dr. Carol Routledge, Chief Medical and Scientific Officer, commented on the study.

“IM injection of SPL026 may provide greater convenience for physicians, as well as potentially improve the treatment experience for some patients. This study seeks to identify a target dose of SPL026, administered via IM injection, that is well tolerated and delivers a consistent breakthrough psychedelic experience. By understanding parameters such as the duration and intensity of the psychedelic experience, we will be able to explore the potential application of IM SPL026 for treating mental health conditions.”

George Tziras, Chief Executive Officer, added,

“Patient access is core to our mission. It is reflected in our decision to focus on short-duration psychedelics delivered through different administration routes, with the goal of maximizing patient reach and convenience. With the Phase IIa study of IV SPL026 in Major Depressive Disorder now completed and results anticipated very soon, we are a step closer to understanding the potential efficacy of SPL026 as a depression treatment. These proof-of-concept results, combined with the results of our other SPL026 studies, will help guide our future clinical development and commercialization strategy.”

Small Pharma is a biotechnology company progressing a pipeline of short-acting psychedelic-assisted therapies for the treatment of mental health conditions. The company’s current focus is on exploring new therapeutic approaches for depression.

Small Pharma (DMT) is up over 5.50 per cent, trading at C$0.10 at 2:31 pm EST.


More From The Market Herald

" @ the Bell: Tech leads TSX comeback

It was another rocky day for Canada’s main stock index that ultimately ended up in the green thanks to a lead powered by
Geomega Resources - President & CEO, Kiril Mugerman

" Geomega Resources (TSXV:GMA) granted $3M for recycling demo plant

Geomega Resources (GMA) has been awarded a $3 million grant from the government of Quebec’s Technoclimat Program.
First Hydrogen Corp. - CEO of Automotive, Steve Gill.

" First Hydrogen (TSXV:FHYD) unveils next gen FCEV images

First Hydrogen (FHYD) has received the initial Generation II images for its hydrogen fuel cell vehicle (FCEV), designed in collaboration with EDAG Group.
The Tugaske Project.

" Gensource Potash (TSXV:GSP) closes non-brokered private placement

Gensource Potash Corporation (GSP) has closed its previously announced non-brokered private placement of units and flow-through common shares.